FOLFIRI


Also found in: Acronyms, Wikipedia.

FOLFIRI

Leucovorin, irinotecan, and fluorouracil, chemotherapeutic agents used to treat solid tumors, such as those arising in the colon or pancreas.
References in periodicals archive ?
In CRYSTAL clinical trial with 600 mCRC patients, to compare the efficacy of cetuximab plus FOLFIRI and FOLFIRI chemotherapy alone, the most common observed side effects were as follows: diarrhea [(36/600 (6.
The original CRYSTAL trial data indicated that metastatic colorectal cancer patients who received a combination of cemximab and FOLFIRI had a 15% reduced risk of disease progression.
Once FOLFIRI was added to cetuximab, patients with wild-type KRAS tumors had an overall response rate of 55%, compared with 32% for those with mutant KRAS tumors.
Vectibix is an epidermal growth factor receptor (EGFR) antagonist approved in India for the treatment of adult patients with wild-type KRAS metastatic colorectal cancer (m-CRC) as first line treatment as monotherapy following disease progression, in wild type RAS m-CRC as first-line combination with FOLFOX and in second line in combination with FOLFIRI after prior treatment with fluoropyrimidine-based chemotherapy (excluding irinotecan), added the company.
32) A study published in 2004 demonstrated similar efficacy of salvage FOLFIRI following first-line FOLFOX and salvage FOLFOX following first-line FOLFIRI, suggesting the particular sequence of these chemotherapeutic regimens was unimportant.
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: Experiences at two-institutions.
The global, randomized, double-blind study compared ramucirumab plus FOLFIRI to placebo plus FOLFIRI as a second-line treatment in patients with mCRC after treatment with bevacizumab, oxaliplatin and a fluoropyrimidine in the first-line setting.
FOLFOX and FOLFIRI are the most widely used combinations.
Of the 348 tumor samples that expressed normal KRAS, one-year progression-free survival rates were 25% and 43% for patients with normal KRAS tumors receiving FOLFIRI (fluorouracil, leucovorin, and irinotecan) and the combination of cetuximab plus FOLFIRI, respectively.